MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor Microenvironment Activable LINker-payload (TMALIN®) ADC technology platform. It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. MediLink focuses their clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients. MediLink is headquartered in Suzhou and has established R&D subsidiaries in Shanghai and Boston.